Condition (MeSH)
Coccidioidomycosis
ClinicalTrials.gov lists 21 trials for Coccidioidomycosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Coccidioidomycosis itself; the rest are tagged with a narrower condition beneath it.
When did Coccidioidomycosis trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Coccidioidomycosis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 4 |
How many Coccidioidomycosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 11 |
| Terminated | 3 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Coccidioidomycosis trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| Pfizer | 2 |
| Caja Costarricense de Seguro Social | 1 |
| F2G Biotech GmbH | 1 |
| F2G Ltd | 1 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Coccidioidomycosis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Olorofim | 3 |
| Nikkomycin Z | 1 |
| IBREXAFUNGERP | 1 |
| VT-1598 | 1 |
| VT-1161 | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluconazol | 4 |
| SUBA itraconazole | 2 |
| Spherule-derived coccidioidin | 1 |
| Sertralin | 1 |
| Conventional itraconazole | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Coccidioidomycosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 18 | 3 |
| Respiratory failure | 14 | 2 |
| COVID-19 | 13 | 2 |
| Acute kidney injury | 10 | 2 |
| Pyrexia | 9 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Coccidioidomycosis? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Back to the History. | The New England journal of medicine | 2017 | Yes |
| Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2008 | Yes |
| The prevalence of cellular immunity to coccidioidomycosis in a highly endemic area. | The Western journal of medicine | 1986 | Yes |
| Coccidioidomycosis: Alias San Joaquin Valley fever. | Medical times | 1979 | Yes |
| [Confirmation of the first Central American cas of coccidioidomycosis]. | Revista medica de Costa Rica | 1951 | Yes |
Showing 5 of 10 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Coccidioidomycosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Coccidioidomycosis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Coccidioidomycosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Coccidioidomycosis | 228123 | Exact | Orphadata Science knowledge files, Product 1 |
| Coccidioidomycosis | 228123 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.